Phase I Clinical Trial of Therapeutic Inducers of Natural Killer Killing (ThINKK) Adoptive Immunotherapy: Feasibility, Safety and Pharmacodynamics in Children Undergoing Allogenic Hematopoietic Transplantation for Leukemia or Neuroblastoma
Latest Information Update: 16 Apr 2026
At a glance
- Drugs Natural killer cell replacements (Primary)
- Indications Leukaemia; Neuroblastoma
- Focus Adverse reactions
- Acronyms ThINKK-01
Most Recent Events
- 16 Apr 2026 New trial record